Cessatech AS (XSAT:CESSA) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:CESSA Cessatech AS XSAT:CESSA
28 GF Score
Price kr10.40
! 2 Warning Signs
View Full Analysis

What is Cessatech AS Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XSAT:CESSA
28GF Score
Cessatech AS XSAT:CESSA
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cessatech AS Business Description

Other Exchanges 8GN:Germany
Address Strandvejen 60, Hellerup, DNK, DK- 2900
Cessatech AS is a pharmaceutical company committed to developing and commercializing evidence-based medicines for children for the treatment of paediatric acute pain. The company is advancing a pipeline comprising three assets, all addressing an unmet medical need in the treatment of children. The main candidate, CT001, a fixed-dose nasal spray for treating acute pain in children, is in the pre-launch phase in the U.S. and the EU. CT002, a non-invasive intranasal sedation for children undergoing medical procedures (e.g., MRI scans), has an approved PIP in the EU. CT003, a topical anaesthetic, is currently in pre-clinical development.
28GF Score

Get the complete analysis for XSAT:CESSA

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.40
Price